Penny Stock Under Rs 10: Avio Smart Market Stack Partners with Huwel Lifesciences to Target Rs 1,000 Crore TB Diagnostics Market
The company has a market cap of over Rs 300 crore. The stock price has surged over 56 per cent in last 3 years.
✨ AI Powered Summary
On Monday, shares of Avio Smart Market Stack Limited (ASMS) fell 3.89 per cent to Rs 9.88 per share from its previous closing of Rs 10.28 per share. The stock’s 52-week high is Rs 19.00 per share and its 52-week low is Rs 9.80 per share.
Avio Smart Market Stack Limited (ASMS), formerly known as Bartronics India Limited, has officially signed a Share Subscription cum Shareholders’ Agreement with Hyderabad-based Huwel Lifesciences. The agreement, finalised on March 2, 2026, formalises a strategic partnership that was originally initiated through a Memorandum of Understanding in September 2025.
Under the terms of the agreement, ASMS will acquire a minority stake in Huwel Lifesciences. The partnership structure entitles ASMS to a defined share of net project revenues generated from orders secured and executed through its institutional engagement and business development efforts. This collaboration marks ASMS’s strategic entry into the broader healthcare and diagnostics sector.
A key focus of the partnership is the Quantiplus® MTB FAST platform, a tuberculosis diagnostic solution developed by Huwel Lifesciences. Recent Health Technology AssesSMEnt findings from the Department of Health Research under the Ministry of Health & Family Welfare indicate that the platform enables testing at approximately Rs 340 per sample. This is significantly more cost-effective than the molecular testing systems currently used in government programmes, which typically cost between Rs 700 and Rs 1,000 per test.
Add DSIJ as your preferred news source on G o o g l e
Add NowThe Quantiplus platform is compatible with open RT-PCR systems, allowing the Indian government to leverage thousands of RT-PCR machines installed nationwide during the COVID-19 pandemic. This compatibility enables rapid deployment without the need for proprietary hardware or significant additional capital expenditure.
With India conducting nearly one crore tuberculosis tests annually under the National TB Elimination Programme (NTEP), the annual molecular TB diagnostics market is estimated at around Rs 1,000 crore. The Health Technology Assessment findings could position Huwel’s platform strongly within the public molecular TB diagnostics segment, potentially enabling central and state authorities to consider it for wider national adoption.
The company has a market cap of over Rs 300 crore. The stock price has surged over 56 per cent in last 3 years.
Disclaimer: The article is for informational purposes only and not investment advice.